Stock RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Delayed Nasdaq
Other stock markets
 01:36:54 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.02 USD +1.00% Intraday chart for Reviva Pharmaceuticals Holdings, Inc. -2.15% -41.29%
Apr. 15 Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia CI
Apr. 15 Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
PR
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
BU
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
AQ
Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia
CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
AQ
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
AQ
Reviva to Present at the UBS Virtual CNS Day
AQ
Reviva to Present at the 36th Annual ROTH Conference
AQ
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
AQ
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
AQ
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
AQ
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones
AQ
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
AQ
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
AQ
Reviva Pharmaceuticals Closes $30 Million Registered Direct Offering
MT
Reviva Pharmaceuticals Holdings, Inc. announced that it has received $2.999942 million in funding
CI
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon
MT
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading
MT
Sector Update: Health Care
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVPH Stock
  4. News Reviva Pharmaceuticals Holdings, Inc.